HeartMate 3 Left Ventricular Assist System
ABBOTT MEDICAL · Decision date Aug 23, 2017
What did the FDA approve?
FDA approved PMA P160054 for the HeartMate 3 Left Ventricular Assist System on August 23, 2017, with applicant Abbott Medical. The approval covers the device as indicated for short-term hemodynamic support, described as bridge to transplant or bridge to myocardial recovery, in patients with advanced refractory left ventricular heart failure.
The source statement does not identify a supplement type or reason, so this record reflects the original PMA scope rather than a change to a previously approved system. The statement reports the device's indicated purpose; it does not provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
Approval for the HeartMate 3 Left Ventricular Assist System. This device is indicated for providing short-term hemodynamic support (e.g., bridge to transplant or bridge to myocardial recovery) in patients with advanced refractory left ventricular heart failure.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 23, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160054
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- DSQ
- Decision code
- APPR
- Decision date
- Aug 23, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ventricular (assist) bypass.
- Applicant
- Abbott Medical
- Product code
- DSQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160054 received
Application receipt date recorded by FDA.
P160054 · FDA decision
APPR
P160054/S134 · Related supplement
HeartMate 3 Left Ventricular Assist System
P160054/S135 · Related supplement
HeartMate 3 LVAS
P160054/S136 · Related supplement
HeartMate 3 Left Ventricular Assist System
Timeline entries are records held by MedtechLedger for P160054. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160054
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HeartMate 3 Left Ventricular Assist SystemP160054/S134 | ABBOTT MEDICAL | PMA supplement | Sep 9, 2026 | FDA |
HeartMate 3 LVASP160054/S135 | ABBOTT MEDICAL | PMA supplement | Oct 1, 2026 | FDA |
HeartMate 3 Left Ventricular Assist SystemP160054/S136 | ABBOTT MEDICAL | PMA supplement | Oct 19, 2026 | FDA |
Explore the linked device profile
Other records with product code DSQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EXCOR Pediatric Ventricular Assist DeviceP160035/S054 | Berlin Heart, Inc. | PMA supplement | Oct 30, 2026 | FDA |
CentriMag Circulatory Support SystemP170038/S034 | Abbott | PMA supplement | Oct 30, 2026 | FDA |
EXCOR Pediatric VADP160035/S061 | Berlin Heart, Inc. | PMA supplement | Oct 28, 2026 | FDA |
EXCOR Pediatric Ventricular Assist DeviceP160035/S060 | Berlin Heart, Inc. | PMA supplement | Oct 23, 2026 | FDA |
EXCOR Pediatric VADP160035/S056 | Berlin Heart, Inc. | PMA supplement | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6035 Stoneridge Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P160054
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




